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Abstract
Background: Low concentrations of selenium (Se) in
humans have been associated with risk of cancer.
Selenoprotein mRNAs can potentially be regulated by
Se status.
Methods: Se status, GPx1 Pro198Leu and Sep15
1125G/A genetic polymorphism and human (h)GPx1,
hGPx3, hSep15 and hSeP1 transcript levels in periph-
eral leukocytes of 33 males with bladder cancer and
47 healthy male controls were analysed.
Results: All the subjects expressed detectable sele-
noprotein mRNA concentrations in leukocytes. Signi-
ficantly lower expression of hGPx1, hGPx3, hSep15
and hSeP1 in leukocytes of bladder cancer patients
compared to controls was observed. hGPx1, hGPx3
and hSep15 expression was significantly lower in
non-smokers in the control group compared with
smokers in the control group. A positive relationship
between expression of all studied genes was also
observed in non-smoking controls. Expression of
hGPx3 and hSep15 gradually increased with tumour
grade in patients with cancer. We did not find any
association between selenoprotein mRNA levels, Se
status and selenoprotein genetic polymorphism.
Conclusions: This study showed significant down-
regulation of hGPx1, hGPx3, hSep15 and hSeP1
mRNA levels in leukocytes of patients with bladder
cancer compared to controls. Selenoprotein transcript
levels in circulating leukocytes of patients with blad-
der cancer and controls revealed no potential impact
of Se status on selenoprotein expression.
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Introduction
Bladder cancer is the seventh most common cancer
in men in the world, and fourth most common in
Poland. The incidence is higher in Polish males than
in males from Central and Eastern European coun-
tries, but similar to that observed in Western and
Southern Europe and the US (1). Well known risk
factors for bladder cancer include tobacco smoking,
occupational exposure to aromatic amines from
rubber or paint and chronic infections with schisto-
soma haematobium. Some additional risk factors,
such as diet and nutritional habits have also been
considered (2).
Selenium (Se) is a dietary trace element that is
essential for human health (3). Low Se concentrations
measured in blood, toenails and hair have been asso-
ciated with lung, prostate and colorectal cancer (4),
although epidemiological studies on Se status and
bladder cancer risk showed contradictory results (5).
One of the proposed anticancer mechanisms of Se
suggests that there are antioxidative properties of
selenoproteins. Se, genetically encoded as the 21st
aminoacid selenocysteine, is reportedly present at the
active sites of 25 selenoproteins in humans, including
five Se-dependent glutathione peroxidases: cytosolic
glutathione peroxidase (GPx1), extracellular plasma
glutathione peroxidase (GPx3), gastrointestinal GPx2,
phospholipid hydroperoxide-reducing GPx4, oilfacto-
ry epithelial GPx6, and also selenoprotein P (SeP),
15 kDa selenoprotein (Sep15), three iodothyronine
deiodinases, three thioredoxin (TrR) reductases and
additional selenoproteins (6).
Differences in the expression of selenoprotein
mRNAs can reflect dietary Se supply. Both GPx1 and
GPx3 transcript levels rapidly decrease in cases of Se
deficiency, whereas GPx2 mRNA and GPx4 mRNA
levels are fairly resistant to deficiency (7, 8). This hier-
archy of selenoproteins with respect to Se status may
be important in the formation of different tumours,
especially since selenoproteins show tissue-specific
expression profiles (8). In vitro and animal studies
suggest that low levels of selenoprotein transcripts in
response to low Se concentrations have been asso-
ciated with loss of mRNA stability, and degradation
during non-sense-mediated decay (NMD) process (7,
8). Of the 25 known human selenoprotein mRNAs, 14
are thought to be sensitive to NMD (9). Single nucleo-
tide polymorphisms, potentially modifying transcrip-
tion processes, have also been observed in genes
encoding for selenoproteins (10).
Special emphasis has recently been placed on the
application of circulating white blood cell (WBC)
transcriptome patterns. Transcriptomic studies clearly
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Table 1 Demographics of the study population.
Controls (ns47) Cancer (ns33) p-Value
Age, years 49.1"17.4 67.6"9.7 -0.0001
Smoking habit
Yes 13 (27.7%) 13 (39.4%) 0.335
No 34 (72.3%)a 20 (60.6%)b
BMIc, kg/m2 25.1"4.0 26.7"3.3 0.120
Se, ng/mL plasma 54.3"14.6 50.5"23.0 0.282
GPx1, U/L plasma 22.9"3.7 22.0"7.2 0.434
GPx3, U/g Hb 0.200"0.040 0.167"0.036 0.0008
GPx1
Pro198Pro 27 (58.7%)d 13 (39.4%) 0.058
Pro198Leu 18 (39.1%) 15 (45.5%)
Leu198Leu 1 (2.2%) 5 (15.1%)
Sep15
1125G/G 20 (43.5%) 21 (63.6%) 0.141
1125G/A 23 (50.0%) 9 (27.3%)
1125A/A 3 (6.5%) 3 (9.1%)
aThe non-smoking group includes 2 ex-smokers, who quit smokingG5 years before the investigation; bthe non-smoking group
includes 15 ex-smokers, who quit smokingG5 years before the diagnosis of cancer, smoking history of 1 individual is missing;
cBMI data on 3 controls are missing; dGPx1 genotyping data for 1 control is missing. Hb, hemoglobin.
show that various cluster genes can be significantly
expressed in WBCs (11). This allows genomic finger-
prints to be easily obtained to explore the different
responses to nutritional status and environmental
exposure. Gene expression patterns may be useful for
defining biological processes associated with human
health and disease. Evenson et al. (12) found that
mRNA concentrations of rat selenoproteins in whole
blood were comparable to concentrations detected in
the major organs. Decreased rat GPx1 mRNA concen-
trations in rat blood and liver under conditions of die-
tary deficiency of Se indicated that WBC mRNA
concentrations could be a biomarker of Se exposure
in rats. Lampe et al. (13) showed that active exposure
to tobacco smoke is associated with a biological
relevant mRNA expression signature. Therefore, we
investigated human (h)GPx1, hGPx3, hSep15, and
hSeP1 transcript concentrations in circulating leuko-
cytes to determine whether gene expression in
healthy individuals differs from that in patients with
bladder cancer who present with different smoking
habits. Also, we wished to determine if there is an
impact of Se status and GPx1 Pro198Leu, Sep15
1125G/A genetic polymorphism on expression of
selenoprotein mRNA.
Materials and methods
Study population
Male patients with bladder cancer and healthy male controls
were recruited from the Department of Urology, Medical
University, Lodz, and from the Nofer Institute of Occupation-
al Medicine, Lodz, respectively. All patients were not under-
going intravenous and/or intrabladder chemotherapy
administration and with transurethral resection. Patients pre-
sented with transitional cell carcinoma (TCC) of the urinary
bladder. Cases (ns33) and controls (ns47) were selected
with respect to smoking habits in order to provide similar
numbers of smokers and non-smokers. The non-smokers
included those who had never smoked and those who pre-
viously smoked, but quit smoking G5 years prior to entering
the study. The study participants completed a questionnaire
that provided information on demographic characteristics
including age, body mass index (BMI) and smoking history.
The characteristics of the study population are presented in
Table 1. The Regional Ethics Committee for Scientific
Research approved the study protocol, and a written
informed consent was obtained from all participants.
Se status
Blood samples were collected into Venoject heparinized
(lithium heparin) test tubes, free from trace elements, for
determination of Se status. Blood was also collected into
EDTA tubes for isolation of RNA and DNA. Plasma Se con-
centrations were measured according to Neve et al. (14)
using graphite furnace atomic absorption spectrometry
(Solaar 989 QZ apparatus, Unicam, Thermo Scientific, War-
saw, Poland). The method was validated using reference
material consisting of lyophilized human reference serum
samples of Seronorm (Nycomed Pharma AS, Oslo, Nor-
way). Red blood cell (RBC) and plasma GPx activities were
measured spectrophotometrically according to the method
of Paglia and Valentine (15) with modification by Hopkins
and Tudhope (16).
RNA and DNA isolation and cDNA synthesis
Total RNA and genomic DNA were isolated from whole
blood using the QIAamp RNA Blood Mini Kit and QIAamp
DNA Blood Mini Kit (Qiagen, Syngen Biotech, Wroclaw,
Poland), respectively, according to the manufacturer’s
instructions. The concentration and purity of isolated RNA
and DNA were determined spectrophotometrically. cDNA
was synthesized on 250 ng RNA with Omniscript RT Kit (Qia-
gen, Syngen Biotech, Poland), oligo dT15–18 primer and
RNase-free DNase I (Promega, Symbios, Gdansk, Poland).
Selenoprotein mRNAs expression
Expression of the hGPx1, hGPx3, hSep15 and hSeP1 genes
was quantified with the iQ5 real-time PCR detection system
(Bio-Rad, Warsaw, Poland) using glyceraldehyde 3-phos-
phate dehydrogenase (hGAPDH) as the endogenous control.
This allowed for stable expression levels of RNA isolated
from peripheral blood leukocytes. Forward and reverse prim-
ers for target genes and TaqMan probes were designed
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Table 2 Oligonucleotide primers and TaqMan probes used for real-time PCR.
Gene GI number Primers and probes sequencea Amplicon
size, bp
hGPx1 41406083 F–GCATCAGGAGAACGCCAAGAAC 144
R–CGCAGGAAGGCGAAGAGAGG
P–CCCGCACCGTTCACCTCGCACTTC
hGPx3 89903006 F–GAACTCAGAGATCCTTCCTACCC 106
R–CTGCTCTTTCTCTCCATTGACATC
P–CCGACCAGGTGGAGGCTTTGTCCC
hSep15 42741647 F–TTTGGGCTACGGTTGTTGTTG 103
R–AGTTGCTAGAAAAGCCTAACTCTC
P–TGCCTCCGATGAAAACTCTGCCCC
hSepP1 62530390 F–GCCTTCATCACCACCATAAGC 121
R–ATACATCTCTTTCGACAGAGCTTC
P–TCAGCATAGGCAGGGTCACCCAGA
hGAPDH 83641890 F–GGACCTGACCTGCCGTCTAG 101
R–TGTAGCCCAGGATGGCCCTTG
P–CCTCCGACGCCTGCTTCACCACCT
aF, forward 59–39; R, reverse primer 59–39; P, TaqMan probe 59–39 (6-FAM–TAMRA); h, human; GPx1, cytosolic glutathione
peroxidase; GPx3, plasma glutathione peroxidase; Sep15, 15 kDa selenoprotein; SeP1, selenoprotein P; GAPDH, glyceralde-
hyde 3-phosphate dehydrogenase.
with Beacon Designer 7.0 (PREMIER Biosoft Int, Bio-Rad,
Poland) according to the GenBank genetic sequence data-
base. The amplicon sequence complied with exon-exon
boundaries, whenever possible (Table 2). All samples were
amplified in triplicate. Samples from the controls and cancer
patients were amplified simultaneously on the same plate.
Calculated PCR efficiencies were: 99% for hGPx3, 97% for
hSeP1 and 95% for hGPx1, hSep15 and hGAPDH. mRNA
expression data were evaluated by means of two calculation
methods. Reference gene-normalized relative quantitation
with efficiency correction was calculated using Q-Gene, a
Microsoft Excel-based software application coded in Visual
Basic (17). Calibrator-normalized relative expression for esti-
mating up- and down-regulation of gene expression in the
patients with bladder cancer was calculated using REST 2005
Software, Version: 1.9.10 (The Gene Quantification website,
www.gene-quantification.info).
Genotyping
GPx1 Pro198Leu (rs 1050450) primers and probes were
designed with Beacon Designer 7.0 (PREMIER Biosoft Int,
Bio-Rad, Poland) according to the GenBank genetic
sequence database. Genetic polymorphism was analysed
using Molecular Beacon Real-Time PCR. Oligonucleotide
sequences for PCR primers and fluorescent probes were:
forward primer 59–TGACGGTGTGCCCCTACG–39, and reverse
primer 59–CCGAGACAGCAGCACTGC–39, probe C 59–(6-Fam)
CGCGATCAGGCACAGCTGGGCCCTTGAGACGATCGCG (Da-
bcyl)–39, probe T 59–(Hex) CGCGATCAGGCACAGCTGAG-
CCCTTGAGACGATCGCG (Dabcyl)–39. Sep15 1125G/A
polymorphism (rs 5859) was analysed using the PCR-RFLP
assay. Oligonucleotide sequences for PCR primers were:
forward 59–GCCTGCTCCTCAGAGTCTC–39 and reverse 59–
AAACATGAAAGAACAAACCAGAAG–39. The ampliconswere
digested with FspBI (Fermentas, ABO, Gdansk, Poland) and
the digestion products (360 bp, 198 bp, 162 bp) were analy-
sed in 1.5% agarose gel using Molecular Imager Gel Doc and
ChemiDoc Systems and Quantity One software (Bio-Rad,
Poland).
Statistical analysis
Statistical analyses were performed with GraphPad Prism
Version 5.01 (GraphPad Software, Inc., San Diego, CA, USA;
www.graphpad.com). For comparison of the study groups,
an unpaired t-test, one-way analysis of variance (for bio-
chemical analyses) and the Mann-Whitney U-test, the Krus-
kal-Wallis test (for gene expression analyses) and Fisher’s
exact test were used. Correlations were assessed using Pear-
son (for biochemical analyses) or Spearman (for gene
expression analyses) analysis. For all the tests, a two-sided
p-0.05 was used for determining statistical significance.
Results
Smoking habits and BMI were similar in both groups.
Thirty-three patients with TCC of the urinary bladder,
with different grading (G) and staging (T), were exam-
ined. The majority of bladder cancer cases were char-
acterized by low degree of neoplasm (G1) and clinical
progression (T1) (ns14 and ns24, respectively).
Eight patients with grade G2 and nine patients with
grade G3 presented with a high degree of neoplasia.
Invasive characteristics of bladder tumours were seen
in four patients with stage T2 and three patients with
grade T3. Histopathological data for grading two of
the patients was missing.
Gene expression
All the subjects expressed measurable selenoprotein
mRNA concentrations in blood leukocytes, with large
inter-individual variations in gene expression. The
highest concentration of gene transcripts in circulat-
ing leukocytes was observed for the hGPx1 and
hSep15 genes. The lowest concentration was attri-
butable to the hGPx3 and hSeP1 genes. We observed
significant down-regulation of hGPx1, hGPx3, hSep15
and SeP1 mRNA in leukocytes from patients with
bladder cancer when compared to controls. hSeP1
and hGPx3 showed the highest down-regulation in
the bladder cancer group compared to controls, with
mean factors of 0.480 and 0.546, respectively. hSep15
showed down-regulation in the bladder cancer group,
compared to the control group, by a mean factor of
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Table 3 Differences in selenoprotein mRNA expression normalised to hGAPDHa and selenoprotein mRNA relative expres-
sionb from leukocytes of patients with bladder cancer and controls.
Gene Controls, ns47 Cancer, ns33 p-Valuea Expression ratio (SE) p-Valueb
hGPx1
Median 0.435 0.372 0.190 0.778 (0.360–1.637) 0.067
25% percentile 0.247 0.265
75% percentile 0.718 0.425
Mean"SD 0.683"0.705 0.404"0.222
hGPx3
Median 0.0018 0.0012 0.019 0.546 (0.198–1.641) 0.002
25% percentile 0.0009 0.0006
75% percentile 0.0031 0.0019
Mean"SD 0.0026"0.0028 0.0013"0.0010
hSep15
Median 0.205 0.187 0.01 0.592 (0.469–1.082) -0.0001
25% percentile 0.168 0.132
75% percentile 0.283 0.210
Mean"SD 0.279"0.227 0.173"0.078
hSeP1
Median 0.0023 0.0013 -0.0001 0.480 (0.246–0.901) -0.0001
25% percentile 0.0017 0.0009
75% percentile 0.0038 0.0019
Mean"SD 0.0045"0.0068 0.0019"0.0020
aReference gene-normalised relative quantification with efficiency correction; bcalibrator-normalised relative expression.
Figure 1 Selenoprotein mRNA expression normalised to hGAPDH in leukocytes in relation to different grades of bladder
cancer (G1, ns14; G2, ns8; G3, ns9).
(A) mRNA hGPx1, ps0.124; (B) mRNA hGPx3, ps0.023*; (C) mRNA hSep15, ps0.008*; (D) mRNA hSeP1, ps0.114.
0.592 and hGPx1 by a mean factor of 0.778 (Table 3).
We did not observe differences in expression of the
four selenoprotein encoding genes in patients with
TCC of the bladder and non-invasive (T1) and invasive
(T1qT3) characteristics. However, expression of sele-
noprotein mRNA in leukocytes of patients with TCC
gradually increased with tumour grade, showing sta-
tistical significance for hGPx3 (ps0.023) and hSep15
(ps0.008) (Figure 1B and C). Comparison of G1 and
G3 tumour grades showed significant up-regulation
of hGPx3 (2.7-fold; ps0.045) and hSep15 (2.4-fold;
ps0.040) (data not shown). In the control group,
significant correlation between expression levels of
the selenoproteins (hGPx1/hGPx3, hGPx1/hSep15,
hGPx1/hSeP1, hGPx3/hSep15, hGPx3/hSeP1, hSep15/
hSeP1) were found. However, in patients with cancer,
the only significant correlation was found between
hGPx3 and hSep15 (rs0.350, ps0.05) (Table 4).
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Table 4 Correlation between selenium status and selenoprotein mRNA expression normalised to hGAPDH in leukocytes from
patients with bladder cancer and controls.
Correlation Controls, ns47 Cancer, ns33
r p-Value r p-Value
Se status
GPx1/Se 0.114 0.444 0.334 0.057
GPx3/Se 0.468 0.0009 0.343 0.051
Selenoprotein mRNAs expression and Se status
hGPx1/Se 0.180 0.226 0.001 0.995
hGPx3/Se 0.178 0.230 –0.061 0.734
hSep15/Se 0.101 0.501 –0.007 0.710
hSeP1/Se 0.159 0.287 0.069 0.702
hGpx1/GPx1 –0.223 0.132 0.133 0.459
hGPx3/GPx3 0.006 0.967 –0.018 0.922
Selenoprotein mRNAs expression
hGPx1/hGPx3 0.797 -0.0001 0.029 0.871
hGPx1/hSep15 0.768 -0.0001 0.316 0.074
hGPx1/hSeP1 0.425 0.003 0.186 0.299
hGPx3/hSep15 0.791 -0.0001 0.350 0.05
hGPx3/hSeP1 0.453 0.001 0.279 0.116
hSep15/hSeP1 0.583 -0.0001 0.455 0.008
Se status
Se status in the study participants was assessed using
plasma Se concentration, GPx3 activity, and GPx1
activity in RBCs. In both cases and controls, neither
Se concentration or GPx1 activity differed significant-
ly. Plasma GPx3 activity was significantly lower
(p-0.0008) in patients with bladder cancer compared
with controls (Table 1). Se status did not differ
between patients with bladder cancer with different
tumour grades (G1, G2 and G3) and characteristics of
muscle invasion (T1 and T2qT3) (data not shown).
There was no significant correlation between Se con-
centrations and GPx activities in both study groups.
A significant association between plasma Se con-
centration and GPx3 activity in plasma (rs0.468;
p-0.0009) was found in controls (Table 4). An anal-
ysis performed to assess the relationship between
selenoprotein mRNA concentrations and Se status,
indicated by Se concentrations and plasma activity of
GPx1 RBC and GPx3, revealed no significant correla-
tion in either of the groups.
Genetic polymorphism
The distribution of GPx1 Pro198Leu and Sep15
1125G/A genotypes in the controls and patients with
bladder cancer did not differ significantly (Table 1).
We found no effect of genetic polymorphisms ofGPx1
and Sep15 on Se status or selenoprotein mRNA con-
centrations (data not shown).
Impact of smoking on Se status and gene
expression
To investigate the potential impact of tobacco smok-
ing on Se status and selenoprotein gene expression,
we divided both groups into non-smokers and smok-
ers. There were no differences between selenoprotein
transcript concentrations in bladder cancer patients,
relative to smoking habits. However, in the control
group, hGPx1, hGPx3 and hSep15 expression was
significantly lower in smokers compared with non-
smokers. hSep15 showed the highest down-regula-
tion in smokers compared with non-smokers by a
mean factor of 0.645. hGPx3 was down-regulated by
a mean factor of 0.457, and hGPx1 by a mean factor
of 0.386 (Table 5). Comparison between non-smoking
controls and cancer patients showed significant down-
regulation of expression of all the selenoprotein
encoding genes in leukocytes in patients with bladder
cancer, while cancer patients who smoked presented
with significantly lower expression of hGPx1 and
hSep15 compared with controls that smoked. GPx3
activity was significantly lower in both non-smoking
and smoking patients with cancer compared to their
respective control groups (Table 5). The observed cor-
relations between the expression level of all the sele-
noprotein mRNAs in the control group were almost
entirely related to non-smokers (Table 6).
Discussion
Se and selenoproteins are widely implicated in the
aetiology of cancer, suggesting several hypothesis for
the anticarcinogenic activity of this trace element. Se
and selenoprotein concentrations in blood or blood
compartments were lower in cancer patients than in
controls (4). The mechanism of the anticarcinogenic
activity of Se in bladder neoplasms can be explained
by a possible direct and indirect effect on bladder
mucosa, via plasma, reducing the concentration of
carcinogens. In this study, plasma Se concentra-
tion and GPx1 activity did not differ in patients with
bladder cancer and controls.
Data concerning selenoprotein mRNA expression in
malignant and non-malignant tissue still provides
insufficient information about bladder tumours. There
are no good data on the levels of different selenopro-
tein transcript concentrations in tumours and benign
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Table 5 Differences in selenoprotein mRNA expression normalised to hGAPDHa, selenoprotein mRNA relative expressionb
and selenium status in patients with bladder cancer and controls with respect to smoking status.
Non-smokers, Smokers, p-Valuea Expression ratio (SE) p-Valueb
ns34 ns13
Mean"SD Mean"SD
Controls
Se, ng/mL 56.0"12.9 50.0"18.23 0.069
GPx1, U/g Hb 22.4"3.3 24.2"4.4 0.094
GPx3, U/L plasma 0.200"0.041 0.201"0.037 0.943
hGPx1 0.813"0.732 0.342"0.508 -0.0001 0.386 (0.201–1.243) -0.0001
hGPx3 0.0031"0.0031 0.0012"0.0016 0.0002 0.457 (0.238–1.878) -0.0001
hSep15 0.293"0.162 0.240"0.0350 0.0001 0.645 (0.456–0.914) -0.0001
hSeP1 0.0042"0.0053 0.0053"0.0100 0.529 0.934 (0.465–2.018) 0.716
Non-smokers, Smokers, p-Valuea Expression ratio (SE) p-Valueb
ns20 ns13
Mean"SD Mean"SD
Cancer
Se, ng/mL 48.6"22.3 53.5"24.6 0.672
GPx1, U/g Hb 22.1"6.6 21.9"8.4 0.839
GPx3, U/L plasma 0.172"0.035c 0.164"0.038c 0.495
hGPx1 0.343"0.089c 0.497"0.321c 0.246 1.252 (0.660–2.380) 0.300
hGPx3 0.0015"0.0010c 0.0012"0.0009 0.387 0.924 (0.265–2.508) 0.847
hSep15 0.156"0.069c 0.200"0.087c 0.191 1.526 (0.809–1.654) 0.239
hSeP1 0.0018"0.0025c 0.0020"0.0014 0.146 1.356 (0.781–2.746) 0.230
aReference gene-normalised relative quantification with efficiency correction; bcalibrator-normalised relative expression;
cstatistically significant differences (p-0.05) between controls and cancer patients. Hb, hemoglobin.
Table 6 Correlation between selenoprotein mRNA expression normalised to hGAPDH from leukocytes of controls in relation
to smoking status.
Correlation Non-smokers, ns34 Smokers, ns13
r p-Value r p-Value
hGPx1/hGPx3 0.651 -0.0001 0.388 0.190
hGPx1/hSep15 0.559 0.0006 0.418 0.155
hGPx1/hSeP1 0.508 0.002 0.226 0.459
hGPx3/hSep15 0.614 0.0001 0.720 0.006
hGPx3/hSeP1 0.560 0.0006 0.187 0.541
hSep15/hSeP1 0.775 -0.0001 0.264 0.384
samples. It is presumed that tissue Se status, as well
as genetic and epigenetic alterations such as dele-
tions and hypermethylation can influence mRNA
concentrations of selenoproteins (18, 19). Our find-
ings may support the hypothesis that there is low
expression of selenoprotein mRNAs in neoplasms.
We found that leukocytes from patients with bladder
cancer showed significant down-regulation in hGPx1,
hGPx3, hSep15 and hSeP1 expression compared to
leukocytes from controls. The results from patients
with TCC of the urinary bladder showed up-regulation
of tissue GPx in cases with different grades of tumour
and invasive characteristics (20). Our findings con-
cerning hGPx3 and hSep15 expression in leukocytes
of patients with bladder cancer, which correlated with
tumour grade, add to the data concerning expression
of selenoprotein genes in peripheral leukocytes of
patients with different grades of bladder TCC.
It is well known that selenoproteins are unevenly
distributed amongst different tissues. The most ubi-
quitous is GPx1, Sep15 is found primarily in the liver
and prostate, kidney is the main source of GPx3 and
SeP is synthesised in the liver. Different selenoprotein
mRNA expression levels may be associated with the
hierarchy of selenoproteins in response to Se status
(8). The present study indicates that there is a large
inter-individual variation in selenoprotein gene
expression in human circulating leukocytes with
specific expression patterns. The observed higher
expression of mRNA of hGPx1 and hSep15 in leuko-
cytes compared with hGPx3 and hSeP may also sug-
gest a first-line of action for GPx1 and Sep15 in
antioxidant defences in WBCs. Inter-individual differ-
ences in selenoprotein expression in leukocytes,
observed in our study, can be associated with hetero-
geneous WBC populations used in this investigation,
including lymphocytes, monocytes, and granulocytes.
Each subset of leukocytes presents a unique pattern
of gene expression related to its specific function (21).
Different expression of selenoprotein mRNAs in
patients with cancer of the urinary bladder and con-
trols may reflect the relative proportions of specific
WBC subpopulations. In addition, the results of our
study did not confirm a functional significance for
GPx1 Pro198Leu and Sep15 1125G/A genetic poly-
morphisms, which could potentially modify Se status
and/or hGPx1 and hSep15 expression in peripheral
leukocytes. To date, genetic polymorphisms within
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selenoproteins have been found in hGPx1, hGPx3,
hSep15, and hSeP1 genes. The functional effect of
these polymorphisms was confirmed primarily in
studies of cell cultures (10).
Some studies have indicated that specific gene
transcription in circulating blood leukocytes is asso-
ciated with cigarette smoking (13, 22, 23). It has been
observed that smoking can reduce Se concentrations
within the body, due to possible interactions with
arsenic that is present in tobacco smoke (23). We did
not find significant differences in plasma Se concen-
trations, RBC GPx1 or plasma GPx3 activity between
non-smokers and smokers with bladder cancer and
controls. In TCC of the bladder, there were no differ-
ences in selenoprotein gene expression between non-
smokers and smokers. However, in the control group,
hGPx1, hGPx3 and hSep15 showed significantly
higher expression in leukocytes from non-smokers
compared with expression leukocytes from smokers.
Moreover, significant correlation between expression
levels of all the studied selenoprotein mRNAs were
generally seen in non-smoking healthy controls.
A growing number of studies have investigated dif-
ferent populations of WBC transcriptome patterns.
This readily accessible human biological material can
be easily used and is supposed to be a biomarker of
nutritional status (24, 25). The study performed on
rats by Evenson et al. (12) indicated that WBC rGPx1
mRNA concentrations can be a useful biomarker of
the effects of Se exposure. However, our results did
not confirm the hypothesis that the expression of
selenoprotein mRNA in circulating leukocytes can
reflect Se status. Correlation between mRNA hGPx1,
hGPx3, hSep15, hSeP1 and Se status showed no sig-
nificant association in patients with TCC of the urinary
bladder or healthy controls. Recent results by Ravn-
Haren et al. (23, 24) also indicated lack of alterations
in selenoprotein mRNA expression in WBCs after
short- and long-term supplementation with Se. Fol-
lowing one week of non-organic or organic forms of
Se supplementation in healthy young Danish men,
there were no differences in expression of GPx1, cyto-
solic TrR1 and SeP1 in leukocytes.
In conclusion, significant differences in expression
of hGPx1, hGPx3, hSep15 and SeP1 in leukocytes of
patients with bladder cancer when compared with
controls appear to be associated with smoking status.
Moreover, in non-smoking controls, a significant
positive relationship between expression of all the
studied genes was observed. We did not find a
functional significance for GPx1 and Sep15 genetic
polymorphisms with respect to Se status or gene
expression in leukocytes. Transcript concentrations in
circulating leukocytes of bladder cancer patients and
controls did not reveal a potential impact of Se status
on expression of selenoproteins. Differences in age
and the relatively low number of study participants
were limitations of our study. Despite this, the use of
WBCs, including leukocytes, warrants further investi-
gations in a larger group of patients of both genders
with different baseline Se status, and in patients with
different types of neoplasms. The elucidation of the
potential interactions between selenoprotein tran-
script concentrations and selenoprotein concentra-
tions and activity, in relation to several genetic
polymorphisms of selenoproteins, should be also
included.
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